Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

£300m raised for ABV V:

This article was originally published in Clinica

Executive Summary

Abingworth has closed what is said to be the largest life sciences venture fund in Europe, rallying a total of £300m ($587m) in investment. Abingworth Bioventures V LP (ABV V), the company's eighth life sciences fund, will invest in bio- and medical technology firms of varying stages of development in Europe and the US. Abingworth says it plans to make over 20 venture investments, ranging between £7.5-20m for each investment.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel